# Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor

> **NCT06218069** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Radboud University Medical Center** · enrollment: 20 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Sasanlimab
- **RADIATION:** non-ablative radiotherapy
- **DRUG:** [89Zr]Zr-crefmirlimab berdoxam

## Key facts

- **NCT ID:** NCT06218069
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02
- **Primary completion:** 2025-12
- **Final completion:** 2027-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-11-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06218069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06218069, "Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06218069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*